Methylprednisolone
Brand names: Solu-Medrone (IV/IM), Depo-Medrone (depot IM/intra-articular), Medrone (oral)
Methylprednisolone is a synthetic intermediate-acting glucocorticoid used for its anti-inflammatory and immunosuppressive effects across a wide range of inflammatory, allergic, autoimmune and endocrine conditions, including as replacement or suppression therapy.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds the intracellular glucocorticoid receptor and modulates transcription of genes involved in inflammation and immunity, suppressing leucocyte function and the production of inflammatory mediators.
Prescribing in practice
- Do not stop prolonged or high-dose therapy abruptly because of the risk of adrenal suppression and Addisonian crisis; the dose must be tapered, and a steroid emergency card and sick-day guidance provided.
- Has minimal mineralocorticoid activity compared with hydrocortisone, so it is less likely to cause fluid retention but is not a first choice for primary adrenal replacement.
- Long-term use increases the risk of osteoporosis, hyperglycaemia, infection, peptic ulceration, mood disturbance and adrenal suppression, so use the lowest effective dose for the shortest time.
Monitoring
Monitor weight, blood pressure, blood glucose, signs of infection and, in prolonged therapy, bone health and growth in children.
Counselling the patient
- Carry a steroid treatment card and never stop the medicine suddenly.
- Seek urgent advice if unwell, feverish or vomiting, as the dose may need to be increased.
- Report symptoms of infection promptly, as steroids can mask them.
Evidence & guidelines
Glucocorticoids are long-established anti-inflammatory and immunosuppressive agents, and MHRA advice highlights the need for steroid emergency cards and structured withdrawal to prevent adrenal crisis.
Reference: NICE CG186 (Multiple Sclerosis); BSR Guidelines on Rheumatoid Arthritis; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- DOAC Score for Selecting Direct Oral Anticoagulant in Non-Valvular AF · Anticoagulation
- IABP Timing Assessment · Mechanical Circulatory Support
- SIRS Criteria and Sepsis Definition · Sepsis
- Steroid Dose Equivalence · Medications
- Lille Model for Alcoholic Hepatitis · Hepatology
- Steroid Conversion Calculator · Drug Dosing
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016